نتایج جستجو برای: cyp51a

تعداد نتایج: 195  

2018
Jochem B. Buil Jan Zoll Paul E. Verweij Willem J. G. Melchers

Aspergillus diseases are often caused by Aspergillus fumigatus. Azoles are the mainstay of therapy, but the management of aspergillosis is hampered by the emergence of azole resistance. Rapid detection of azole resistance might benefit treatment outcome by early treatment modifications. However, the yield of fungal culture in invasive aspergillosis is low and susceptibility testing requires sev...

Journal: :Antimicrobial agents and chemotherapy 2016
Maiken Cavling Arendrup Rasmus Hare Jensen Manuel Cuenca-Estrella

ASP2397 is a new compound with a novel and as-yet-unknown target different from that of licensed antifungal agents. It has activity against Aspergillus and Candida glabrata. We compared its in vitro activity against wild-type and azole-resistant A. fumigatus and A. terreus isolates with that of amphotericin B, itraconazole, posaconazole, and voriconazole. Thirty-four isolates, including 4 wild-...

2016
Fabio Gsaller Peter Hortschansky Takanori Furukawa Paul D Carr Bharat Rash Javier Capilla Christoph Müller Franz Bracher Paul Bowyer Hubertus Haas Axel A Brakhage Michael J Bromley

Azole drugs selectively target fungal sterol biosynthesis and are critical to our antifungal therapeutic arsenal. However, resistance to this class of drugs, particularly in the major human mould pathogen Aspergillus fumigatus, is emerging and reaching levels that have prompted some to suggest that there is a realistic probability that they will be lost for clinical use. The dominating class of...

2015
Azam Fattahi Farideh Zaini Parivash Kordbacheh Sasan Rezaie Mahin Safara Roohollah Fateh Shirin Farahyar Ali Kanani Mansour Heidari

BACKGROUND Voriconazole Resistance (VRC-R) in Aspergillus flavus isolates impacts the management of aspergillosis, since azoles are the first choice for prophylaxis and therapy. However, to the best of our knowledge, the mechanisms underlying voriconazole resistance are poorly understood. OBJECTIVES The present study was designed to evaluate mRNA expression levels of cyp51A and mdr1 genes in ...

Journal: :The Journal of antimicrobial chemotherapy 2014
J Lescar I Meyer K Akshita K Srinivasaraghavan C Verma M Palous D Mazier A Datry A Fekkar

OBJECTIVES Voriconazole, itraconazole and posaconazole are members of the azole family and widely used for the treatment of aspergillosis. They act by inhibiting the activity of the fungal Cyp51A enzyme. The emergence of environmental azole-resistant Aspergillus fumigatus strains raises major concerns for human health. METHODS Recently, a new cyp51A-mediated resistance mechanism (namely TR46/...

2013
Michael Weig Utz Reichard Raimond Lugert Martin Kuhns Jürgen Held Silke Peter Ulrike Schumacher Dieter Buchheidt Orsolya Benedek

72 Since the mid-1990s, a steady increase in the occurrence of itraconazole resistant Aspergillus 73 fumigatus isolates has been observed in clinical contexts leading to therapeutic failure in the 74 treatment of aspergillosis. This increase has been predominantly linked to a single allele of 75 the cyp51A gene, termed ‘TR/L98H’ which is thought to have arisen through the use of 76 agricultural...

Journal: :Journal of clinical microbiology 2005
Sergey V Balashov Rebecca Gardiner Steven Park David S Perlin

Aspergillus fumigatus is an important cause of life-threatening invasive fungal disease in patients with compromised immune systems. Resistance to itraconazole in A. fumigatus is closely linked to amino acid substitutions in Cyp51A that replace Gly54. In an effort to develop a new class of molecular diagnostic assay that can rapidly assess drug resistance, a multiplexed assay was established. T...

Journal: :The Journal of antimicrobial chemotherapy 2013
Yanan Zhao Christen R Stensvold David S Perlin Maiken C Arendrup

OBJECTIVES Triazole resistance in Aspergillus fumigatus has been increasing. We explored the A. fumigatus azole resistance profiles in bronchoalveolar lavage (BAL) fluid samples from Danish patients examined for aspergillosis. METHODS A total of 94 BAL samples from 87 patients were evaluated by galactomannan (GM) test and A. fumigatus CYP51A profiling by PCR. RESULTS Aspergillus spp. were i...

2015
W. S. Moye-Rowley

Infections caused by the filamentous fungus Aspergillus fumigatus are a significant clinical issue and represent the second most-common form of fungal infection. Azole drugs are effective against this pathogen but resistant isolates are being found more frequently. Infections associated with azole resistant A. fumigatus have a significantly increased mortality making understanding drug resistan...

Journal: :The Journal of infectious diseases 2012
Maiken C Arendrup Rasmus H Jensen Katharina Grif Marianne Skov Tacjana Pressler Helle K Johansen Cornelia Lass-Flörl

Azole resistance in Aspergillus terreus isolates was explored. Twenty related (MB) and 6 unrelated A. terreus isolates were included. CYP51A sequencing and RAPD genotyping was performed. Five MB isolates were itraconazole susceptible, whereas the minimum inhibitory concentrations (MICs) for 15 MB isolates were elevated (1-2 mg/L). Voriconazole and posaconazole MICs were 0.5-4 and 0.06-0.5 mg/L,...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید